1998
DOI: 10.1002/(sici)1096-9098(199802)67:2<112::aid-jso7>3.0.co;2-d
|View full text |Cite
|
Sign up to set email alerts
|

Multiple bilobar liver metastases: cryotherapy for residual lesions after liver resection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
18
0
1

Year Published

1999
1999
2013
2013

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 41 publications
(19 citation statements)
references
References 16 publications
0
18
0
1
Order By: Relevance
“…Median survival was 32 months with 2-year survival of 60%. 32 Because it is unlikely that resection alone will be curative in the majority of patients with colorectal metastases, it is of vital importance to continue to investigate the use of regional and/or systemic chemotherapy as adjunctive treatment. We have recently reported early results of a randomized trial of HAI chemotherapy (floxuridine and dexamethasone) plus systemic 5-FU and leucovorin vs. systemic chemotherapy alone as an adjuvant therapy after complete resection, with significantly improved 2-year survival of 85%, compared with 69% in those receiving systemic chemotherapy alone.…”
Section: -Year Survival In Patients Withmentioning
confidence: 99%
“…Median survival was 32 months with 2-year survival of 60%. 32 Because it is unlikely that resection alone will be curative in the majority of patients with colorectal metastases, it is of vital importance to continue to investigate the use of regional and/or systemic chemotherapy as adjunctive treatment. We have recently reported early results of a randomized trial of HAI chemotherapy (floxuridine and dexamethasone) plus systemic 5-FU and leucovorin vs. systemic chemotherapy alone as an adjuvant therapy after complete resection, with significantly improved 2-year survival of 85%, compared with 69% in those receiving systemic chemotherapy alone.…”
Section: -Year Survival In Patients Withmentioning
confidence: 99%
“…If the initial liver resection was R0 ("curative"), a second R0-resection of intra-and extrahepatic recurrent disease, respectively, resulted in 57% and 32% 5-year survival values from the time of re-intervention. For the future, new chemotherapeutic agents, refined immunotherapy protocols [119], preoperative chemoem-bolization, radioimmuno-guided surgery [120], ex situand ante-situ resection [121,122], or the combination of resection and cryotherapy [123,124] all need to be evaluated in multicenter, multidisciplinary trials. tive randomized trial, Lorenz has failed to achieve a significant survival benefit using adjuvant hepatic arterial infusion with 5-fluorouracil (5-FU) and folinic acid after R0 liver resection.…”
Section: (Neo)-adjuvant Treatment and Further Perspectivesmentioning
confidence: 99%
“…The curative potential with cryotherapy in CLMs had been further demonstrated by the 10-year survival of 13% [82]. The available literature on treatment of CLMs with hepatic cryotherapy reports median, 1-, 2-, 3-, 4-, 5-, and 10-year overall survivals of 18 -33 months [56,57,[59][60][61]63,64,66,[70][71][72][73]77,78,[80][81][82][83]85], 78% -92% [56,58,61,63,66,[70][71][72]80,82,83,86], 47% -66% [61,63,66,[70][71][72]80,83,86,87], 29% -50% [56,58,60,63,66,72,80,8...…”
Section: Survivalmentioning
confidence: 99%